Answers are grounded in this paper and cite their sources.
Immunizations with CD8 T cell epitopes reduced lung viral load in mice, suggesting mucosal vaccines could enhance T cell immunity against SARS-CoV-2.
The emergence of SARS-CoV-2 variants has challenged the current spike protein–focused COVID-19 vaccine strategy due to neutralizing antibody escape and waning antibody-mediated immunity. In contrast, T cell–mediated immunity targeting conserved epitopes may offer broad and long-lasting protection. However, whether T cells alone can provide sufficient protection remains unclear. Here, we identified both Omicron BA.1–specific and ancestral (Wuhan)–conserved CD8 T cell epitopes in the SARS-CoV-2 spike protein and evaluated them as carrier-protein fusion vaccines in mouse models. Subcutaneous immunizations with two CD8 epitope peptides substantially lowered lung viral load and conferred protection against low-dose viral challenge, but not against high-dose challenge. Notably, intranasal boosting—with or without adjuvant—enhanced lung resident memory T cell responses and conferred potent, durable protection against high-dose infection. These findings emphasize the importance of mucosal vaccination to boost protective T cell immunity against SARS-CoV-2 and support the potential of T cell–based vaccines targeting conserved epitopes for broad immunity against SARS-CoV-2 and other respiratory viral threats.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: